Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck funds Canadian life sciences research
As part of the funding, IRICoR along with MaRS Innovation and the Centre for Drug Research and Development (CDRD) will identify, develop and commercialize technologies in healthcare. Merck
As part of the funding, IRICoR along with MaRS Innovation and the Centre for Drug Research and Development (CDRD) will identify, develop and commercialize technologies in healthcare. Merck
The assays are used to determine hemoglobin variants and diabetes risk, using Bruker´s Matrix-Assisted Laser Desorption Ionization (MALDI) Biotyper platform for clinical mass spectrometry and based on intellectual
BD Simplist prefilled injectables are designed to enhance patient care and safety by minimizing the number of steps in the traditional vial and syringe injection sequence, cutting the
Of €3.6m, €2.7m will be used for balance sheet restructuring and €0.9m will finance the additional production facilities. Piramida CEO Kresimir Hlede said that the investment would mark
The multi-centre study will determine a recommended NEOD001 dose for testing in Phase 2 trials. Prothena president and chief executive officer Dale Schenk said preclinical data indicated NEOD001’s
The collaboration will focus on developing small molecule therapeutics targeting a janus kinase (JAK) family member, TYK2. Sareum CEO Dr. Tim Mitchell said, "The agreement with SRI gives
According to the deal, Novo Nordisk has access to the Kymouse HK and Kymouse HL transgenic human antibody mouse strains, the combination of which are used to create
Lonza will manufacture BNC101 at Slough facility in the UK. Bionomics CEO and managing director Dr Deborah Rathjen said, "The start of manufacturing activities for BNC101 signals a
Alitair provided additional details regarding its ‘398 patent specific to formulations of benzonatate. At present, benzonatate is the only non-narcotic prescription cough product available, according to the company
The novel chemical entity XEN402 is designed to inhibit the SCN9A sodium channel. Teva Pharmaceutical Industries has exclusive worldwide license to XEN402 that earlier demonstrated to relieve from